透明质酸钠产品市场 - 副产品（外用、注射）、应用（药品 [皮肤科、眼科、骨科、泌尿科]、化妆品）、最终用途（医院、ASC） - 全球预测 2024 - 2032 年

在全球人口快速老化的推动下，基于透明质酸钠的产品市场规模预计在 2024 年至 2032 年间复合年增长率为 7.8%。近年来，由于透明质酸钠具有保湿和润滑特性，对老化皮肤有益，因此对含有透明质酸钠的眼药水的需求显着增长。此外，骨关节炎等关节疾病的盛行率不断上升，促使人们偏好基于透明质酸钠的关节内注射，以缓解疼痛并改善关节活动。美国疾病管制与预防中心(CDC) 表示，到2023 年，美国将有超过3,250 万名成年人患有骨关节炎(OA)。的7%。

此外，消费者越来越意识到透明质酸在护肤和医疗方面的好处。由于对年轻肌肤的渴望和非侵入性抗衰老解决方案的出现，化妆品行业对基于透明质酸钠的真皮填充剂和外用护肤产品的需求正在激增。对微创治疗的日益重视以及护肤品中对天然成分的偏好将进一步推动该行业的成长。

透明质酸钠产品产业分为产品、应用、最终用途和地区。

从应用来看，2024 年至 2032 年间，眼科领域的市场规模将达到 7.7% 的成长率。透明质酸钠具有保持水分和提供润滑的能力，在眼科製剂（包括人工泪液和眼内溶液）中越来越受到重视。此外，眼部药物输送系统的进步和对微创治疗的需求不断增长进一步推动了产品的采用。

就最终用途而言，门诊手术中心领域的透明质酸钠产品市场在 2024 年至 2032 年期间将达到 8% 的成长率。由于成本效益和住院时间减少，人们对门诊手术的偏好日益增加。微创手术技术的进步也增加了以透明质酸钠为基础的产品在眼科手术、骨科介入和门诊美容治疗等手术中的使用。

由于促进使用安全有效的护肤品和眼科解决方案的严格法规，欧洲基于透明质酸钠的产品行业规模在预测期内将实现 7.2% 的复合年增长率。此外，该地区消费者对化妆品和医疗产品中天然和永续成分的偏好正在增加。此外，製药公司和研究机构之间的策略合作伙伴关係促进了创新配方和输送系统的开发，以提高欧洲透明质酸钠产品的功效和多功能性。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 提高人们对护肤和健康的认识
    • 技术进步
    • 美容手术的需求不断增长
    • 骨科和眼科手术数量不断增加
  • 产业陷阱与挑战
    • 治疗费用高
    • 潜在的副作用和过敏反应
• 成长潜力分析
• 监管环境
• 技术景观
• 波特的分析
• PESTEL分析
• 报销场景
• 未来市场趋势

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品分类，2018 年 - 2032 年

• 主要趋势
• 可注射
• 专题
• 其他产品

第 6 章：市场估计与预测：按应用划分，2018 年 - 2032 年

• 主要趋势
• 药品
  • 眼科
  • 骨科
  • 皮肤科
  • 泌尿科
  • 其他药品
• 化妆品

第 7 章：市场估计与预测：按最终用途，2018 - 2032 年

• 主要趋势
• 医院
• 门诊手术中心
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2018 年 - 2032 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 亚太地区其他地区
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地区
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿联酋
  • 中东和非洲其他地区

第 9 章：公司简介

• ASHLAND INC.
• Allergan, Inc.
• Anika Therapeutics, Inc
• Bohus BioTech AB
• Cadila Pharmaceuticals
• Ferring B.V.
• Fidia Farmaceutici S.p.A.
• GALDERMA
• LG Chem, Ltd.
• Syner-Med (Pharmaceutical Products) Ltd.
• Zimmer Biomet

Sodium Hyaluronate-based Products Market size is set to observe 7.8% CAGR between 2024 and 2032, driven by the rapidly aging population worldwide. Of late, the demand for ophthalmic solutions containing sodium hyaluronate due to its moisturizing and lubricating properties, which are beneficial for aging skin is significantly growing. Additionally, the rising prevalence of joint disorders, such as osteoarthritis has spurred the preference for sodium hyaluronate-based intra-articular injections to provide pain relief and improve joint mobility. The Centers for Disease Control and Prevention (CDC) stated that over 32.5 million adults in the U.S. lived with osteoarthritis (OA) in 2023. Globally, OA affected more than 500 million people, which accounts 7% of the world's population.

Moreover, there is an increasing awareness among consumers about the benefits of hyaluronic acid in skincare and medical treatments. The cosmetic industry is experiencing a surge in demand for sodium hyaluronate-based dermal fillers and topical skincare products, driven by the desire for youthful-looking skin and the availability of non-invasive anti-aging solutions. The growing emphasis on minimally invasive treatments and the preference for natural ingredients in skincare products will further propel the industry growth.

The sodium hyaluronate -based products industry is divided into product, application, end-use and region.

By application, the market size from the ophthalmology segment will record a 7.7% growth rate between 2024 and 2032. The increasing prevalence of eye disorders, such as dry eye syndrome and cataracts is necessitating effective solutions for lubrication and hydration. Sodium hyaluronate, with its ability to retain moisture and provide lubrication is gaining prominence in ophthalmic formulations, including artificial tears and intraocular solutions. Moreover, advancements in ocular drug delivery systems and the rising demand for minimally invasive treatments are further driving the product adoption.

With respect to end-use, the sodium hyaluronate-based products market from the ambulatory surgical centers segment will witness 8% growth rate throughout 2024-2032. There is a rising preference for outpatient surgical procedures, driven by cost-effectiveness and reduced hospital stays. Advancements in minimally invasive surgical techniques have also increased the use of sodium hyaluronate-based products for procedures like ophthalmic surgeries, orthopedic interventions, and aesthetic treatments performed in ambulatory settings.

Europe sodium hyaluronate -based products industry size will witness 7.2% CAGR during the forecast period, attributed to stringent regulations for promoting the use of safe and effective skincare and ophthalmic solutions. Additionally, the consumer preference for natural and sustainable ingredients in cosmetic and medical products is increasing across the region. Moreover, strategic partnerships between pharmaceutical companies and research institutions have led to the development of innovative formulations and delivery systems for enhancing the efficacy and versatility of sodium hyaluronate-based products in Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Base estimates & calculations
• 1.3 Data collection
• 1.4 Forecast calculations
• 1.5 Data sources
  • 1.5.1 Primary
  • 1.5.2 Secondary
    • 1.5.2.1 Paid sources
    • 1.5.2.2 Public sources

Chapter 2 Executive Summary

• 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing awareness about skincare and wellness
    • 3.2.1.2 Technological advancements
    • 3.2.1.3 Growing demand for aesthetic procedures
    • 3.2.1.4 Rising number of orthopedic and ophthalmic surgeries
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of treatment
    • 3.2.2.2 Potential side effects and allergic reactions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Porter's analysis
  • 3.6.1 Supplier power
  • 3.6.2 Buyer power
  • 3.6.3 Threat of new entrants
  • 3.6.4 Threat of substitutes
  • 3.6.5 Industry rivalry
• 3.7 PESTEL analysis
• 3.8 Reimbursement scenario
• 3.9 Future market trends

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Injectable
• 5.3 Topical
• 5.4 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Pharmaceuticals
  • 6.2.1 Ophthalmology
  • 6.2.2 Orthopedic
  • 6.2.3 Dermatology
  • 6.2.4 Urology
  • 6.2.5 Other pharmaceuticals
• 6.3 Cosmetics

Chapter 7 Market Estimates and Forecast, By End-Use, 2018 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
  • 8.5.4 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 ASHLAND INC.
• 9.2 Allergan, Inc.
• 9.3 Anika Therapeutics, Inc
• 9.4 Bohus BioTech AB
• 9.5 Cadila Pharmaceuticals
• 9.6 Ferring B.V.
• 9.7 Fidia Farmaceutici S.p.A.
• 9.8 GALDERMA
• 9.9 LG Chem, Ltd.
• 9.10 Syner-Med (Pharmaceutical Products) Ltd.
• 9.11 Zimmer Biomet